Oppenheimer Issues Pessimistic Forecast for InflaRx (NASDAQ:IFRX) Stock Price

InflaRx (NASDAQ:IFRX - Get Free Report) had its price target lowered by Oppenheimer from $6.00 to $3.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Oppenheimer's price objective suggests a potential upside of 272.67% from the stock's current price.

Several other equities research analysts have also recently commented on IFRX. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st. Raymond James cut InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price for the company. in a research report on Thursday. Cantor Fitzgerald initiated coverage on InflaRx in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price for the company. Finally, Guggenheim upped their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Wednesday, March 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $6.60.

InflaRx Stock Performance

Shares of NASDAQ IFRX traded down $0.05 during trading hours on Thursday, hitting $0.81. The stock had a trading volume of 508,905 shares, compared to its average volume of 271,076. The company has a market capitalization of $54.04 million, a P/E ratio of -0.75 and a beta of 1.57. The firm's 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.82. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. As a group, analysts expect that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Two Sigma Securities LLC acquired a new position in shares of InflaRx in the fourth quarter valued at $28,000. Walleye Capital LLC acquired a new position in InflaRx during the fourth quarter worth $51,000. Cubist Systematic Strategies LLC acquired a new position in InflaRx during the fourth quarter worth $55,000. XTX Topco Ltd acquired a new position in InflaRx during the first quarter worth $38,000. Finally, Geode Capital Management LLC raised its stake in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after acquiring an additional 11,900 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.